Bruker (NASDAQ:BRKR - Get Free Report) released its quarterly earnings results on Thursday. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.01, Zacks reports. Bruker had a return on equity of 21.52% and a net margin of 9.41%. Bruker updated its FY 2025 guidance to 2.670-2.720 EPS.
Bruker Price Performance
Shares of BRKR traded down $1.11 during mid-day trading on Monday, reaching $50.04. The company had a trading volume of 2,044,498 shares, compared to its average volume of 1,412,424. Bruker has a twelve month low of $48.07 and a twelve month high of $94.86. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The company's 50-day moving average is $57.56 and its 200-day moving average is $60.48. The company has a market capitalization of $7.59 billion, a P/E ratio of 24.06, a P/E/G ratio of 3.81 and a beta of 1.16.
Analyst Ratings Changes
Several brokerages recently weighed in on BRKR. UBS Group began coverage on Bruker in a research note on Tuesday, December 10th. They set a "neutral" rating and a $66.00 target price for the company. Wells Fargo & Company decreased their target price on Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. Barclays decreased their target price on Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Bank of America increased their target price on Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, December 13th. Finally, The Goldman Sachs Group upgraded Bruker from a "sell" rating to a "neutral" rating and set a $60.00 target price for the company in a research note on Thursday, December 5th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $70.50.
Check Out Our Latest Stock Analysis on BRKR
About Bruker
(
Get Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Read More
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
